Subgroups and Phenotypes of Myasthenia Gravis

EP: 1.Myasthenia Gravis and Underlying Pathophysiology

Now Viewing

EP: 2.Subgroups and Phenotypes of Myasthenia Gravis

EP: 3.Atypical Presentation of Myasthenia Gravis and Importance of Early Diagnosis

EP: 4.Targeting Different Mechanisms of Action to Treat Myasthenia Gravis

EP: 5.Efgartigimod In Myasthenia Gravis

EP: 6.Complement Inhibitors in Myasthenia Gravis

This is a video synopsis of a discussion involving Neelam Goyal, MD, who delves into the clinical presentation and classification of myasthenia gravis (MG). Dr. Goyal outlines various ways to categorize MG patients, emphasizing the importance of understanding the disease's pathophysiology.

Patients with MG can be classified based on phenotype and antibody detection. Approximately 85% of MG cases exhibit detectable antibodies. Age of onset is another criterion for subgrouping, with MG typically manifesting between ages 30 to 50. Notably, a predilection for females is observed when onset occurs at age 30, while at age 50, there is a higher incidence among men. MG can develop at any age, warranting specific classifications such as juvenile onset MG for those younger than 18, late onset for those over 50, and very late onset for those after 65.

Dr. Goyal underscores the fatigable nature of MG, where symptoms, including ocular manifestations like double vision and ptosis, worsen towards the end of the day. Key features indicating a potential MG diagnosis include the combination of ocular symptoms, pure motor involvement, and a history of fatigability.

This comprehensive overview by Dr. Goyal provides clinicians with valuable insights into the diverse clinical presentations of MG, aiding in more accurate and timely diagnoses, and highlighting the need for tailored approaches in managing this complex autoimmune disorder.

Video synopsis is AI-generated and reviewed by NeurologyLive® editorial staff.